Compare Biogen Inc (BIIB) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Robinhood Markets, Inc. — how do they compare? Biogen Inc trades at $191.22 (market cap $28.34B), while Robinhood Markets, Inc. trades at $116.06 (market cap $101.85B). The key difference: Robinhood Markets, Inc. is far larger — about 3.6× Biogen Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.
| BIIB | HOOD | |
|---|---|---|
Market Cap | $28.34B | $101.85B |
Sector | Health | Technology |
52-Week High | $216.63 | $152.46 |
52-Week Low | $122.68 | $65.16 |
Enterprise Value | $30.62B | $103.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Robinhood (HOOD) trades at $109.86, down 1.88% today, with strong technical momentum showing bullish moving averages and key support at $108. Fundamentally, the company demonstrates robust growth with 2025 revenue reaching $4.47 billion and net income of $1.88 billion, though valuation metrics remain elevated with a P/E of 53.33. Recent earnings show mixed results with a Q1 2026 miss but positive Q3 and Q4 2025 beats. The company's Robinhood Chain launch and potential asset-backed securities offering represent significant growth initiatives.
The outlook remains positive with analyst consensus at Buy (73% rating) and a $112.07 price target suggesting modest upside. Key opportunities include continued revenue diversification beyond crypto and new product offerings. Primary risks include valuation concerns, crypto market volatility exposure, and competitive pressures in the brokerage space. Operating cash flow improvement to $1.64 billion in 2025 provides financial stability for growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
